Issue 8, 2023

A BODIPY-based probe for amyloid-β imaging in vivo

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease, and the efficient detection of amyloid-β (Aβ) plaques can greatly enhance diagnosis and therapy. Most reported probes used to detect Aβ are based on the N,N-dimethylamino group. As such, the design of new Aβ-recognition units facilitates the recognition of Aβ. Herein, we present an Aβ recognition unit [4-(Boc-amino) benzene] used to develop BocBDP. BocBDP can recognize and image Aβ plaques both in vitro and in vivo through the interaction with amino acid residues Lys16 (K16), Val18 (V18), and Glu22 (E22). The hydrogen bonding interaction (1.9 Å) between the carbonyl oxygen atom in the Boc unit and the amino acid residue K16 allows BocBDP to bind strongly to Aβ, resulting in a five-fold fluorescence enhancement and a high affinity (Kd = 67.8 ± 3.18 nM). BocBDP can cross the BBB and image Aβ for at least 2 hours. We anticipate that our Aβ recognition unit will help improve the design of probes that specifically recognize Aβ.

Graphical abstract: A BODIPY-based probe for amyloid-β imaging in vivo

Supplementary files

Article information

Article type
Research Article
Submitted
29 dec 2022
Accepted
08 mrt 2023
First published
10 mrt 2023
This article is Open Access
Creative Commons BY license

Org. Chem. Front., 2023,10, 1903-1909

A BODIPY-based probe for amyloid-β imaging in vivo

M. Zhu, G. Zhang, Z. Hu, C. Zhu, Y. Chen, T. D. James, L. Ma and Z. Wang, Org. Chem. Front., 2023, 10, 1903 DOI: 10.1039/D2QO02032G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements